# Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM.

> **NCT04628936** · PHASE2 · COMPLETED · sponsor: **Kezar Life Sciences, Inc.** · enrollment: 18 (actual)

## Conditions studied

- Polymyositis
- Dermatomyositis

## Interventions

- **DRUG:** KZR-616

## Key facts

- **NCT ID:** NCT04628936
- **Lead sponsor:** Kezar Life Sciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-04
- **Primary completion:** 2023-03-10
- **Final completion:** 2023-06-12
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2025-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04628936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04628936, "Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04628936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*